
Triplet Therapy Shows Promise for Advanced TNBC Regardless of PD-L1 Status
A phase 2 study, ATRACTIB (NCT04408118), investigated a novel triple combination therapy for advanced triple-negative breast cancer (TNBC), demonstrating encouraging antitumor activity and a manageable safety profile in patients, predominantly those with …